{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:07:23Z","timestamp":1790615243771,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:00:00Z","timestamp":1562457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Antithyroid drug (ATD)\u2010induced agranulocytosis is a life\u2010threatening adverse drug reaction. Previous studies suggested that HLA\u00a0genotypes may play an important role in ATD\u2010induced agranulocytosis. To examine the associations between HLA\u00a0genotypes and ATD\u2010induced agranulocytosis, we conducted a systematic review and meta\u2010analysis of pharmacogenomics studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the MEDLINE, Embase and CENTRAL databases on 16 June 2018 for case\u2013control studies on the associations between HLA\u00a0genotypes with ATD\u2010induced agranulocytosis. The Newcastle\u2013Ottawa scale was used to evaluate the risk of bias of included studies. We conducted random\u2010effects model meta\u2010analysis to obtain pooled odds ratios (ORs) with 95% confidence intervals (CIs) to determine the associations between HLA\u00a0genotypes and ATD\u2010induced agranulocytosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 5 studies with 142 ATD\u2010induced agranulocytosis cases, 1529 matched ATD\u2010tolerant controls and 5945 healthy controls. The risk of bias of included studies was generally low. ATD\u2010induced agranulocytosis was associated with\n                      <jats:italic>HLA\u2010B*27:05<\/jats:italic>\n                      (OR 10.97; 95% CI 0.75\u2013159.99),\n                      <jats:italic>HLA\u2010B*38:02<\/jats:italic>\n                      (OR 19.85; 95% CI 7.94\u201349.57) and\n                      <jats:italic>HLA\u2010DRB1*08:03<\/jats:italic>\n                      (OR 5.29; 95% CI 3.44\u20138.14). After excluding propylthiouracil, the associations of ATD\u2010induced agranulocytosis with\n                      <jats:italic>HLA\u2010B*27:05<\/jats:italic>\n                      and\n                      <jats:italic>HLA\u2010B*38:02<\/jats:italic>\n                      were strengthened (OR being 20.61 (95% CI 5.21\u201381.58) and 40.59 (95% CI 13.24\u2013124.47), respectively). The associations of ATD\u2010induced agranulocytosis with\n                      <jats:italic>HLA\u2010B*27:05<\/jats:italic>\n                      ,\n                      <jats:italic>HLA\u2010B*38:02<\/jats:italic>\n                      and\n                      <jats:italic>HLA\u2010DRB1*08:03<\/jats:italic>\n                      remained significant when compared to population controls (OR being 7.37 (95% CI 3.86\u201314.07), 36.43 (95% CI 12.80\u2013103.70) and 5.42 (95% CI 2.36\u201312.47), respectively).\n                      <jats:italic>HLA\u2010B*27:05<\/jats:italic>\n                      ,\n                      <jats:italic>HLA\u2010B*38:02<\/jats:italic>\n                      , and\n                      <jats:italic>HLA\u2010DRB1*08:03<\/jats:italic>\n                      alleles were associated with ATD\u2010induced agranulocytosis, especially in carbimazole\/methimazole\u2010induced agranulocytosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>HLA\u2010B*27:05<\/jats:italic>\n                      ,\n                      <jats:italic>HLA\u2010B*38:02<\/jats:italic>\n                      and\n                      <jats:italic>HLA\u2010DRB1*08:03<\/jats:italic>\n                      alleles were associated with ATD\u2010induced agranulocytosis, especially in carbimazole\/methimazole\u2010induced agranulocytosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.13989","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T17:49:01Z","timestamp":1558374541000},"page":"1878-1887","source":"Crossref","is-referenced-by-count":20,"title":["Associations of HLA\u00a0genotypes with antithyroid drug\u2010induced agranulocytosis: A systematic review and meta\u2010analysis of pharmacogenomics studies"],"prefix":"10.1111","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-4008","authenticated-orcid":false,"given":"Wei\u2010Ti","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"},{"name":"Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-0283","authenticated-orcid":false,"given":"Ching\u2010Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chang Gung Memorial Hospital  Linkou Taoyuan Taiwan"},{"name":"College of Medicine Chang Gung University  Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010263431707"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra042972"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1954"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106060-00001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb05823.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/105072504323150787"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2569"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.985649"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4274"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5757"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2010"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.01.001"},{"key":"e_1_2_9_16_1","unstructured":"WellsG SB OCJ RobertsonJ.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analysis.http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed August 8 2018."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8633"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00113-3"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12350-2"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.309"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-5-199603010-00005"},{"key":"e_1_2_9_22_1","volume-title":"The use of the WHO\u2010UMC system for standardised case causality assessment","author":"Uppsala Monitoring Centre","year":"2017"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.80343"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_9_25_1","first-page":"317","article-title":"Standardization of definitions and criteria of causality assessment of adverse drug reactions","volume":"28","author":"Benichou C","year":"1990","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06518.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01720.x"},{"key":"e_1_2_9_28_1","first-page":"354","article-title":"Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis","volume":"19","author":"Waldhauser L","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2694"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baw069"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.10.003"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.004"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03344959"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1297\/cpe.20.39"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000367990"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-017-0004-2"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.733"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13989","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13989","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13989","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:33:54Z","timestamp":1694295234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,7]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/bcp.13989"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13989","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,7]]}}}